Market Spotlight: Esophageal Cancer
Market Spotlight: Esophageal Cancer
$1,318.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2019, there were 578,600 incident cases of esophageal cancer worldwide, and expects that number to increase to 618,900 incident cases by 2028.
- Incidence is higher in males compared to females, and is highest in the Asia region. Merck & Co’s Keytruda, Pinnacle Biologics’ Photofrin, Bristol Myers Squibb’s Opdivo, and Jiangsu Hengrui’s camrelizumab are the only marketed drugs for esophageal cancer. These drugs are administered via the intravenous route.
- The majority of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II, with only one drug in the NDA/BLA phase.
- Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs are administered intravenously, with the remainder being oral and intratumoral formulations.
- High-impact upcoming events for drugs in the esophageal cancer space comprise topline Phase II trial results for ADPA2M4CD8, topline Phase III trial results for Imfinzi, an estimated PDUFA date for tislelizumab, and expected supplemental CHMP opinions for Opdivo and Yervoy.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.3%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 90% of trials in Phase I–II, and only 10% in Phase III–IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for esophageal cancer, with 93 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for esophageal cancer, closely followed by Roche.
CONTENTS
7 OVERVIEW
8 KEY TAKEAWAYS
9 DISEASE BACKGROUND
10 TREATMENT
10 Surgery
10 Radiation therapy
10 Endoscopic therapy
11 Chemotherapy
11 Targeted therapy
11 Immunotherapy
13 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Multiple Drugs for Esophageal Cancer (July 28, 2021)
26 Sintilimab for Esophageal Cancer (June 22, 2021)
28 Tislelizumab for Esophageal Cancer (June 4, 2021)
29 Opdivo for Esophageal Cancer (June 3, 2021)
31 Camrelizumab for Esophageal Cancer (May 28, 2021)
32 Tislelizumab for Esophageal Cancer (January 27, 2021)
34 Keytruda for Esophageal Cancer (September 21, 2020)
36 Opdivo for Esophageal Cancer (September 21, 2020)
38 Opdivo for Esophageal Cancer (September 21, 2020)
40 Keytruda for Esophageal Cancer (August 19, 2020)
41 Opdivo for Esophageal Cancer (August 11, 2020)
43 Opdivo for Esophageal Cancer (August 11, 2020)
44 Yervoy for Esophageal Cancer (August 11, 2020)
47 KEY UPCOMING EVENTS
48 KEY REGULATORY EVENTS
48 Novartis’s Tislelizumab Takes First Step On US Approval Path
48 Scottish Funding Wins for Kite’s CAR-T Tecartus & Five Other Products
48 Keytruda May Stay Competitive In Gastric Cancer Despite Losing Third-Line Claim
48 Keytruda’s Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says
49 Opdivo First-Line Gastric Cancer Claim Used RTOR
49 Merck Builds Keytruda Esophageal Carcinoma Label Under RTOR
49 Opdivo Seeks New Gastric Cancer Uses
50 New Submission For Keytruda In Esophageal Cancer
50 Opdivo First In Gastroesophageal Cancer
51 PROBABILITY OF SUCCESS
52 LICENSING AND ASSET ACQUISITION DEALS
52 China CSPC Subsidiary Out-Licenses Oncology Candidate To Flame Biosciences
52 Amcure Partners Esophageal Cancer Drug In China With Hinova
52 Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market
53 REVENUE OPPORTUNITY
54 CLINICAL TRIAL LANDSCAPE
55 Sponsors by status
56 Sponsors by phase
57 Recent events
59 BIBLIOGRAPHY
60 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of esophageal cancer, 2019–28
15 Figure 2: Incident cases of esophageal cancer, by gender, 2019
19 Figure 3: Overview of pipeline drugs for esophageal cancer in the US
19 Figure 4: Pipeline drugs for esophageal cancer, by company
20 Figure 5: Pipeline drugs for esophageal cancer, by drug type
20 Figure 6: Pipeline drugs for esophageal cancer, by classification
28 Figure 7: Sintilimab for Esophageal Cancer (June 22, 2021): Phase III – ORIENT-15 (Global)
29 Figure 8: Tislelizumab for Esophageal Cancer (June 4, 2021): Phase III – RATIONALE 302
31 Figure 9: Opdivo for Esophageal Cancer (June 3, 2021): Phase III – CheckMate 648
34 Figure 10: Tislelizumab for Esophageal Cancer (January 27, 2021): Phase III – RATIONALE 302
36 Figure 11: Keytruda for Esophageal Cancer (September 21, 2020): Phase III – KEYNOTE-590
38 Figure 12: Opdivo for Esophageal Cancer (September 21, 2020): Phase III – CheckMate-649
40 Figure 13: Opdivo for Esophageal Cancer (September 21, 2020): Phase III – CheckMate-577
41 Figure 14: Keytruda for Esophageal Cancer (August 19, 2020): Phase III – KEYNOTE-590
43 Figure 15: Opdivo for Esophageal Cancer (August 11, 2020): Phase III – CheckMate-577
44 Figure 16: Opdivo for Esophageal Cancer (August 11, 2020): Phase III – CheckMate-649
46 Figure 17: Yervoy for Esophageal Cancer (August 11, 2020): Phase III – CheckMate – 649 (w/Nivolumab)
47 Figure 18: Key upcoming events in esophageal cancer
51 Figure 19: Probability of success in the solid tumors pipeline
54 Figure 20: Clinical trials in esophageal cancer
54 Figure 21: Top 10 drugs for clinical trials in esophageal cancer
55 Figure 22: Top 10 companies for clinical trials in esophageal cancer
55 Figure 23: Trial locations in esophageal cancer
56 Figure 24: Esophageal cancer trials status
57 Figure 25: Esophageal cancer trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of esophageal cancer, 2019–28
17 Table 2: Marketed drugs for esophageal cancer
21 Table 3: Pipeline drugs for esophageal cancer in the US
26 Table 4: Multiple Drugs for Esophageal Cancer (July 28, 2021)
27 Table 5: Sintilimab for Esophageal Cancer (June 22, 2021)
28 Table 6: Tislelizumab for Esophageal Cancer (June 4, 2021)
30 Table 7: Opdivo for Esophageal Cancer (June 3, 2021)
32 Table 8: Camrelizumab for Esophageal Cancer (May 28, 2021)
33 Table 9: Tislelizumab for Esophageal Cancer (January 27, 2021)
35 Table 10: Keytruda for Esophageal Cancer (September 21, 2020)
37 Table 11: Opdivo for Esophageal Cancer (September 21, 2020)
39 Table 12: Opdivo for Esophageal Cancer (September 21, 2020)
40 Table 13: Keytruda for Esophageal Cancer (August 19, 2020)
42 Table 14: Opdivo for Esophageal Cancer (August 11, 2020)
43 Table 15: Opdivo for Esophageal Cancer (August 11, 2020)
45 Table 16: Yervoy for Esophageal Cancer (August 11, 2020)
53 Table 17: Historical global sales, by drug ($m), 2016–20
53 Table 18: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Duchenne Muscular Dystrophy (DMD) 
Sign up to the